A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions

Journal of the National Cancer Institute

Volumn 92, Issue 5, 2000, Pages 418-423

  Mehta, Rajendra G ^a   Williamson, Elizabeth ^b   Patel, Minu K ^a   Koeffler, H Phillip ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOIC ACID; RETINOID; TROGLITAZONE;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CANCER RISK; LIGAND BINDING; NONHUMAN; PRECANCER; PRIORITY JOURNAL;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CARCINOGENS; CHROMANS; ESTRADIOL; FEMALE; LIGANDS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; ORGAN CULTURE TECHNIQUES; PRECANCEROUS CONDITIONS; PROGESTERONE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRETINOIN;

EID: 0034161814     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. I Natl Cancer Inst 1998;90: 1371-88.
2. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPARγ, Mol Cell 1998;1:465-70.
3. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptor-γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
4. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1985;83:835-9.
5. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994;135: 798-800.
6. Tontonoz P, Singer S, Forman B, Sarraf P, Fletcher J, Fletcher CD, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997;94: 237-41.
7. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995;83:813-9.
8. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83:803-12.
9. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997;94:4318-23.
10. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272:3406-10.
11. Seewaldt VL, Johnson BS, Parker MB, Collins SJ, Swisshelm K. Expression of retinoic acid receptor β mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ 1995;6:1077-88.
12. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992;68:397-406.
13. Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, et al. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature 1992; 35:359-61.
14. Marth C, Mayer I, Daxenbichler G. Effect of retinoic acid and 4-hydroxytamoxifen on human breast cancer cell lines. Biochem Pharmacol 1984;33:2217-21.
15. Fontana JA, Miranda D, Mezu AB. Retinoic acid inhibition of human breast carcinoma proliferation is accompanied by inhibition of the synthesis of a Mr 39,000 protein. Cancer Res 1990;50:1977-82.
16. van der Burg B, van der Leede BM, Kwakkenbos-Isbrucker L, Salverda S, deLaat S, van der Saag PT. Retinoic acid resistance of estradiol-independent breast cancer cells coincides with diminished retinoic acid receptor function. Mol Cell Endocrinol 1993;91:149-57.
17. Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, et al. 9-cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res 1994;54:6549-56.
18. Dawson MI, Chao W, Pine P, Jong L, Hobbs PD, Rudd CK, et al. Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res 1995;55:4446-51.
19. Fontana JA. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol 1987;55:136-44.
20. Moon RC, Mehta RG, Rao KV. Retinoids and cancer in experimental animals. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids: biology, chemistry, and medicine. New York (NY): Raven; 1994. p. 573-95.
21. Mehta RG, Liu J, Constantinou A, Thomas CF, Hawthorne M, You M, et al. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 1995;16: 399-404.
22. Mehta RG, Steele V, Kelloff GJ, Moon C. Influence of thiols and inhibitors of prostaglandin biosynthesis on the carcinogen-induced development of mammary lesions in vitro. Anticancer Res 1991;11:587-92.
23. Gerhauser C, Woongchon M, Lee SK, Sun N, Luo Kosmeder J, Luyengi L, et al. Retinoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat Med 1996;1:260-6.
24. Mehta RG, Hawthrone ME, Steele VE. Induction and prevention of carcinogen-induced precancerous lesions in mouse mammary gland organ culture. Methods Cell Sci 1997;19: 19-24.
25. Lin FK, Banerjee MR, Crump LR. Cell cycle-related hormone carcinogen interaction during chemical carcinogen induction of nodule-like mammary lesions in organ culture. Cancer Res 1976;36:1607-14.
26. Telang NT, Banerjee MR, Iyer AP, Kundu AB. Neoplastic transformation of epithelial cells in whole mammary gland in vitro. Proc Natl Acad Sci USA 1979;76:5886-90.
27. Steele VE, Sharma S, Mehta RG, Elmore E, Redpath JL, Rudd C, et al. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J Cell Biochem 1997;26(suppl):23-46.
28. Chatterjee M, Banerjee MR. Influence of hormones on N-(4-hydroxy-phenyl) retinamide inhibition of 7,12-dimethylbenz[a]anthracene transformation of mammary cells in organ culture. Cancer Lett 1982;16:239-45.
29. Landis JR, Stanish WM, Freeman JL, Koch GG. A computer program for the generalized chi-square analysis of categorical data using weighted least squares (GENCAT). Computer Programs Biomed 1976;6:196-231.
30. Sporn MD, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;25:1332-8.
31. O'Shaughnessy JA. Chemoprevention of breast cancer. JAMA 1996;275:1349-53.
32. Costa A, Malone W, Perloff M, Bauranelli F, Campa T, Dossena G, et al. Tolerability of the synthetic retinoid fenretinide (HPR). Eur J Cancer Clin Oncol 1989;25:805-8.
33. Rotmensz N, DePalo G, Formelli F, Costa A, Marubini E, Campa T, et al. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer Clin Oncol 1991;27: 1127-31.
34. Jang M, Cai L, Udeani G, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resvertsol, a natural product derived from grapes. Science 1997;275: 218-20.
35. Spiegelman BM, Hu E, Kim JB, Brun R. PPAR gamma and the control of adipogenesis. Biochimie 1997;79:111-2.
36. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997;8:159-66.
37. Kilgore MW, Tate PL, Pai S, Sengoku E, Price TM. MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Mol Cell Endocrinol 1997;129: 229-35.
38. Altiok S, Xu M, Spiegelman BM. PPARγ induces cell cycle withdrawal: inhibition of E2F/ DP DNA-binding activity via down-regulation of PP2A. Genes Dev 1997;11:1987-98.
39. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
40. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
41. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4:1046-52.
42. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-52.
43. Tontonoz P, Nagy L, Alvarez J, Thomazy V, Evans RM. PPARγ promotes monocyte/ macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-52.
44. van der Burg B, Slager-Davidowv S, van der Leede BM, deLaat SW, van der Daag PT. Differential regulation of AP1 activity by retinoic acid in hormone-dependent and -independent breast cancer cells. Mol Cell Endocrinol 1995; 112:143-52.
45. Li JJ, Dong Z, Dawson MI, Colburn NH. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res 1996;56:483-9.
46. Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-tetinoic acid). N Engl J Med 1991;324:1385-93.
47. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. all-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-9.
48. Mukherjee R, Daview PJ, Crombie DL, Bishoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997;386:407-10.
49. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (targretin): an RXR-elective ligand. Cancer Res 1996;56:5566-70.